E-COMMERCE FUNCTIONALITY TEMPORARILY UNAVAILABLE. US CUSTOMERS PLEASE CALL 1-800-405-3362 TO PLACE AN ORDER. SHIPPING CUTOFF FOR 2018 IS 12/19/2018 1PM EST

REPROCELL StemRNA Hepato

Code: RCDH001
Item out of Stock | Usually dispatched within 24 hours
Loading...
Be the first to review REPROCELL StemRNA Hepato. Write a review

StemRNA Hepato: The world's first commercial human iPS cell-derived hepatocytes

StemRNA Hepato cells are a high-quality, available source of human hepatocytes for drug metabolism or other physiological studies. ReproHepato cells are differentiated from iPS cells, providing a nearly inexhaustible source of hepatocytes with consistent genetics and physiology, unlike primary human hepatocytes that vary considerably from lot-to-lot.

  • Express robust CYP450 enzyme activity including CYP3A4, CYP1A2, CYP2C9, and CYP2C19
  • Demonstrate inducible expression and metabolic CYP450 activity
  • Display high lot-to-lot consistency
  • Possess a long life-span in culture retaining robust metabolic activity

After six days growth of StemRNA Hepato cells in Hepato Culture Medium,the cells have reached maximum maturity and are ready for use in assays. It is recommended to use Hepato Assay Medium for CYP enzyme analysis. These media are specially optimized for culture and assay of ReproHepato human iPSC-derived hepatocytes.

RCDH001N: StemRNA Hepato — Human iPSC-derived Hepatocytes:

  • Derived from RNA-reprogrammed human iPSC (healthy 32-year-old, male)
  • Frozen single cell suspension of nearly mature human hepatocytes
  • 8.25 × 106 cells (enough to seed an entire 96-well plate)
  • Stable "indefinitely" when stored in liquid nitrogen

Product Name

StemRNA Hepato

Catalog Number

RCDH001N

Size

8.25 million cells

Storage and Stability

Store in liquid nitrogen

Related Products

  • CYP Assay Service
  • Hepatotoxicity assay service
  1. Inamura, Mitsuru and Yokoyama, Chikafumi. "Human iPS cell-derived hepatocytes for drug screening." Regenerative Medicine (2013)
  2. Scott, Clay W., Matthew F. Peters, and Yvonne P. Dragan. "Human induced pluripotent stem cells and their use in drug discovery for toxicity testing." Toxicology letters 219.1 (2013): 49-58.

Additional Publications

Presentations

  • Society for Biomolecular Sciences(SBS), 14th AnnualConference and Exhibition 2008 (St. Louis), poster session, April 2008.
  • IBC AsiaÕs 4th Annual Stem Cells Asia Congress (Singapore), oral session, June 2008.
  • ELRIG and SBS Present: Drug Discovery (UK)poster session, September 2008.
  • Advances in Stem Cell Discoveries (San Francisco) oral session, September 2008.
  • Stem Cells: Drug Discovery and Therapeutics (London) oral session, February 2008.
  • Society for Biomolecular Science 15th Annual Conference (France), poster session, Best Poster 2009 Award-winning, April 2009.
  • Stem Cells and Regenerative Medicine Europe (UK), September 2009,Best Poster 2009 Award-winning.
  • MipTec Conference 2009, October 13-15, Basel Invited Lecture.
  • The 74th Annual Scientific Meeting of the Japanese Circulation Society (Kyoto), March 2010.
  • The 130th The Pharmaceutical Society of Japan (Okayama),March 2010.
  • The Society of Toxicology (SOT) 51st Annual Meeting (CA, USA), poster session, March 2012.
  • Safety Pharmacology Society (SPS), 13th annual meeting 2013 (Rotterdam, Netherlands), poster session, September 2013.
  • Automated Patch-Clamp systems and Ion Channel Expressing Cells 2013 (Tokyo), Verbal presentation 2013 Nov.
  • The 7th Takeda Science Foundation Symposium (Osaka), Poster presentation 2014 Jan.
  • Inamura, Mitsuru and Yokoyama, Chikafumi. "Human iPS cell-derived hepatocytes for drug screening." Regenerative Medicine (2013)
  • Scott, Clay W., Matthew F. Peters, and Yvonne P. Dragan. "Human induced pluripotent stem cells and their use in drug discovery for toxicity testing." Toxicology letters 219.1 (2013): 49-58.
Top